跳至主要内容
临床试验/ITMCTR2000004171
ITMCTR2000004171招募中4 期

Explore the best time for ATO to treat PV combined with compound Huangdai tablets

Southern Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. Aged 14–75 years, Newly diagnosed PV with t(15; 17)(q22; q12);
  • 2. Pre-treatment peripheral blood white blood cell(WBC) count < 10 x 10^9/L;
  • 3. Able to complete the entire treatment process;
  • 4. Signed written informed consent provided by the patient or their family.

排除标准

  • 1. Allergy to the drug ingredient or the supplementary material, or having an allergic constitution;
  • 2. Cardiac insufficiency (cardiac contraindications: left-ventricular ejection fraction (L-VEF) < 50%));
  • 3. Inadequate renal reserve (defined as total creatinine > 3 times the institutional upper limit of the normal range);
  • 4. Significant arrhythmias, electrocardiogram (EKG) abnormalities (congenital long QT syndrome; history or presence of significant ventricular or atrial tachyarrhythmia; clinically significant resting bradycardia (< 50 beats per minute);
  • QTc > 450 ms on screening EKG; right bundle branch block plus left anterior hemiblock, bifascicular block);
  • 5. Combined with other malignant tumors;
  • 6. Pregnant and lactating women;
  • 7. Participants in other drug trials in the last 3 months;
  • 8. Suffering from mental illness or other circumstances which render them unable to complete the treatment plan.

研究者

发起方
Southern Hospital

相似试验

Explore the best time for ATO to treat PV combined... | 临床试验